Sugammadex

A comprehensive review of the published human science, including renal studies

Parisa Partownavid, Bryan T. Romito, Willy Ching, Ashley A. Berry, Charles T. Barkulis, Kim Ngan P. Nguyen, Jonathan S. Jahr

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Although neuromuscular block (NMB) allows immobility for airway management and surgical exposure, termination of its effect is limited by and associated with side effects of acetylcholinesterase inhibitors. Sugammadex is a selective relaxant binding agent that has been shown to reverse deep NMB, even when administered 3 minutes following a 1.2 mg/kg dose of rocuronium. This novel drug is a modified gamma cyclodextrin, that through encapsulation process terminates the effects of rocuronium and vecuronium (aminosteroid muscle relaxants), and enables the anesthesiologists rapidly to reverse profound NMB induced by rocuronium or vecuronium, in a "can't ventilate, can't intubate" crisis. In this review, data from published phase 1, 2, and 3 clinical trials are reviewed and presented. In addition, clinical trials on special patient populations (patients with pulmonary disease and renal insufficiency) are evaluated. Each article reviewed will conclude with a discussion of relevance, focus on adverse event profile, and clinical usefulness.

Original languageEnglish (US)
Pages (from-to)298-317
Number of pages20
JournalAmerican Journal of Therapeutics
Volume22
Issue number4
DOIs
StatePublished - Jan 1 2015

Fingerprint

Neuromuscular Blockade
Vecuronium Bromide
Kidney
Phase III Clinical Trials
Clinical Trials, Phase I
Airway Management
Cholinesterase Inhibitors
Lung Diseases
Renal Insufficiency
Clinical Trials
Muscles
Pharmaceutical Preparations
Population
rocuronium
Sugammadex

Keywords

  • cyclodextrins
  • muscle relaxant
  • muscle relaxant reversal
  • rocuronium
  • selective relaxant binding agents
  • sugammadex
  • vecuronium

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sugammadex : A comprehensive review of the published human science, including renal studies. / Partownavid, Parisa; Romito, Bryan T.; Ching, Willy; Berry, Ashley A.; Barkulis, Charles T.; Nguyen, Kim Ngan P.; Jahr, Jonathan S.

In: American Journal of Therapeutics, Vol. 22, No. 4, 01.01.2015, p. 298-317.

Research output: Contribution to journalReview article

Partownavid, Parisa ; Romito, Bryan T. ; Ching, Willy ; Berry, Ashley A. ; Barkulis, Charles T. ; Nguyen, Kim Ngan P. ; Jahr, Jonathan S. / Sugammadex : A comprehensive review of the published human science, including renal studies. In: American Journal of Therapeutics. 2015 ; Vol. 22, No. 4. pp. 298-317.
@article{bf8d3d7501164b03b72f331de197b073,
title = "Sugammadex: A comprehensive review of the published human science, including renal studies",
abstract = "Although neuromuscular block (NMB) allows immobility for airway management and surgical exposure, termination of its effect is limited by and associated with side effects of acetylcholinesterase inhibitors. Sugammadex is a selective relaxant binding agent that has been shown to reverse deep NMB, even when administered 3 minutes following a 1.2 mg/kg dose of rocuronium. This novel drug is a modified gamma cyclodextrin, that through encapsulation process terminates the effects of rocuronium and vecuronium (aminosteroid muscle relaxants), and enables the anesthesiologists rapidly to reverse profound NMB induced by rocuronium or vecuronium, in a {"}can't ventilate, can't intubate{"} crisis. In this review, data from published phase 1, 2, and 3 clinical trials are reviewed and presented. In addition, clinical trials on special patient populations (patients with pulmonary disease and renal insufficiency) are evaluated. Each article reviewed will conclude with a discussion of relevance, focus on adverse event profile, and clinical usefulness.",
keywords = "cyclodextrins, muscle relaxant, muscle relaxant reversal, rocuronium, selective relaxant binding agents, sugammadex, vecuronium",
author = "Parisa Partownavid and Romito, {Bryan T.} and Willy Ching and Berry, {Ashley A.} and Barkulis, {Charles T.} and Nguyen, {Kim Ngan P.} and Jahr, {Jonathan S.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/MJT.0000000000000103",
language = "English (US)",
volume = "22",
pages = "298--317",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Sugammadex

T2 - A comprehensive review of the published human science, including renal studies

AU - Partownavid, Parisa

AU - Romito, Bryan T.

AU - Ching, Willy

AU - Berry, Ashley A.

AU - Barkulis, Charles T.

AU - Nguyen, Kim Ngan P.

AU - Jahr, Jonathan S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Although neuromuscular block (NMB) allows immobility for airway management and surgical exposure, termination of its effect is limited by and associated with side effects of acetylcholinesterase inhibitors. Sugammadex is a selective relaxant binding agent that has been shown to reverse deep NMB, even when administered 3 minutes following a 1.2 mg/kg dose of rocuronium. This novel drug is a modified gamma cyclodextrin, that through encapsulation process terminates the effects of rocuronium and vecuronium (aminosteroid muscle relaxants), and enables the anesthesiologists rapidly to reverse profound NMB induced by rocuronium or vecuronium, in a "can't ventilate, can't intubate" crisis. In this review, data from published phase 1, 2, and 3 clinical trials are reviewed and presented. In addition, clinical trials on special patient populations (patients with pulmonary disease and renal insufficiency) are evaluated. Each article reviewed will conclude with a discussion of relevance, focus on adverse event profile, and clinical usefulness.

AB - Although neuromuscular block (NMB) allows immobility for airway management and surgical exposure, termination of its effect is limited by and associated with side effects of acetylcholinesterase inhibitors. Sugammadex is a selective relaxant binding agent that has been shown to reverse deep NMB, even when administered 3 minutes following a 1.2 mg/kg dose of rocuronium. This novel drug is a modified gamma cyclodextrin, that through encapsulation process terminates the effects of rocuronium and vecuronium (aminosteroid muscle relaxants), and enables the anesthesiologists rapidly to reverse profound NMB induced by rocuronium or vecuronium, in a "can't ventilate, can't intubate" crisis. In this review, data from published phase 1, 2, and 3 clinical trials are reviewed and presented. In addition, clinical trials on special patient populations (patients with pulmonary disease and renal insufficiency) are evaluated. Each article reviewed will conclude with a discussion of relevance, focus on adverse event profile, and clinical usefulness.

KW - cyclodextrins

KW - muscle relaxant

KW - muscle relaxant reversal

KW - rocuronium

KW - selective relaxant binding agents

KW - sugammadex

KW - vecuronium

UR - http://www.scopus.com/inward/record.url?scp=84937550719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937550719&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000103

DO - 10.1097/MJT.0000000000000103

M3 - Review article

VL - 22

SP - 298

EP - 317

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 4

ER -